Engineering dendritic cell vaccines to improve cancer immunotherapy
Dendritic cells (DCs) have been explored as a promising strategy for cancer immunotherapy. In this Perspective, the authors discuss the different types of DCs and their therapeutic potential in the context of vaccines for personalized cancer therapy.
Guardado en:
Autores principales: | Caleb R. Perez, Michele De Palma |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/36a03cc25943495c9a8a8fbc19153abb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
por: Sara Nava, et al.
Publicado: (2021) -
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
por: Elena V. Abakushina, et al.
Publicado: (2021) -
Genetically-engineered “all-in-one” vaccine platform for cancer immunotherapy
por: Aihua Wu, et al.
Publicado: (2021) -
Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.
por: Daiqing Gao, et al.
Publicado: (2014) -
Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
por: Mona Yazdani, et al.
Publicado: (2021)